(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(amc 2024-05-08)
Expected move: +/- 3.74%
@ $109.75
Utstedt: 3 mai 2024 @ 19:06
Avkastning: 0.24%
Forrige signal: mai 3 - 16:27
Forrige signal:
Avkastning: 0.26 %
Live Chart Being Loaded With Signals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally...
Stats | |
---|---|
Dagens volum | 688 899 |
Gjennomsnittsvolum | 622 370 |
Markedsverdi | 6.86B |
EPS | $0 ( 2024-02-28 ) |
Neste inntjeningsdato | ( $4.16 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 18.03 |
ATR14 | $2.96 (2.69%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Gala Renee D | Sell | 1 736 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 1 236 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 700 | Ordinary Shares |
2024-03-07 | Carr Patricia | Sell | 1 768 | Ordinary Shares |
2024-03-05 | Gala Renee D | Sell | 3 622 | Ordinary Shares |
INSIDER POWER |
---|
43.52 |
Last 96 transactions |
Buy: 357 937 | Sell: 150 837 |
Volum Korrelasjon
Jazz Pharmaceuticals PLC Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
SLVO | 0.91 |
GSHD | 0.904 |
DTSS | 0.903 |
DCRC | 0.887 |
FNWD | 0.875 |
AZTA | 0.874 |
NAKD | 0.873 |
MRNA | 0.866 |
BMRN | 0.864 |
PIXY | 0.861 |
10 Mest negative korrelasjoner | |
---|---|
NRDS | -0.922 |
MORF | -0.92 |
HYPR | -0.909 |
MYNA | -0.908 |
SVC | -0.903 |
HAPP | -0.893 |
PETV | -0.891 |
MLTX | -0.889 |
BLBD | -0.889 |
STRL | -0.886 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Jazz Pharmaceuticals PLC Korrelasjon - Valuta/Råvare
Jazz Pharmaceuticals PLC Økonomi
Annual | 2023 |
Omsetning: | $3.83B |
Bruttogevinst: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2023 |
Omsetning: | $3.83B |
Bruttogevinst: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2022 |
Omsetning: | $3.66B |
Bruttogevinst: | $3.12B (85.23 %) |
EPS: | $-3.42 |
FY | 2021 |
Omsetning: | $3.09B |
Bruttogevinst: | $2.65B (85.76 %) |
EPS: | $-5.52 |
Financial Reports:
No articles found.
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.